RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center
Rhea-AI Summary
RenovoRx (Nasdaq: RNXT) announced expansion of commercial adoption of its FDA-cleared RenovoCath device from five active U.S. cancer centers in September 2025 to nine as of Jan 20, 2026, including City of Hope Cancer Center and Moffitt Cancer Center. The RenovoCath device enables the company’s TAMP™ localized chemotherapy delivery approach and is being integrated into oncology programs while related physician interviews and patient stories were publicized. RenovoRx reported approximately $900,000 in sales through September 2025 and says it built a dedicated commercial team by end of 2025 to accelerate adoption. Ongoing Phase III TIGeR-PaC trial sites are not counted among current commercial customers but could convert after full enrollment in H1 2026.
Positive
- Active RenovoCath customers increased from 5 to 9
- Reported sales of $900,000 through September 2025
- Dedicated commercial team fully onboarded by end of 2025
- Major academic centers added: City of Hope and Moffitt
Negative
- Revenue through Sept 2025 remains modest at $900,000
- Commercial rollout required lessons on approvals, training, reimbursement
- Current active customers exclude Phase III trial sites pending enrollment
News Market Reaction
On the day this news was published, RNXT gained 1.96%, reflecting a mild positive market reaction. This price movement added approximately $719K to the company's valuation, bringing the market cap to $37M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
RNXT was down 0.97% while key biotech peers like PSTV, BCAB, RENB, TELO, and TPST all showed positive price changes, and no peers appeared in the momentum scanner, pointing to a stock-specific setup.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 14 | Investor conference | Positive | +1.4% | CEO presentation on commercial adoption and TIGeR-PaC progress. |
| Jan 08 | Clinical data update | Positive | +13.9% | Promising PK/PD data from TIGeR-PaC sub-study at ASCO GI 2026. |
| Dec 11 | Clinical abstract | Positive | +1.6% | Acceptance of TIGeR-PaC sub-study abstract highlighting reduced systemic drug levels. |
| Dec 01 | Investor conference | Positive | -6.6% | Conference presentation with RenovoCath adoption and ~$900k YTD revenue detail. |
| Nov 19 | Investor conference | Positive | -6.4% | Virtual showcase reviewing commercial progress and ~$900k YTD revenue. |
Stock reactions to news have been mixed: positive moves on clinical data and events, but notable declines on some commercial/financial updates.
Over the last few months, RNXT has highlighted commercial and clinical progress for RenovoCath and its TAMP platform. Event-focused news on Jan 14, 2026 and positive TIGeR-PaC data on Jan 8, 2026 and Dec 11, 2025 saw modest to strong gains. In contrast, conference updates with revenue detail on Dec 1 and Nov 19, 2025 coincided with -6.59% and -6.38% moves. Today’s commercial adoption update continues that theme of steady commercialization alongside ongoing Phase III development.
Regulatory & Risk Context
An effective Form S-3 shelf filed on Nov 14, 2025 allows RNXT to offer up to $50,000,000 of mixed securities over time, with at least one prior usage via a 424B5 prospectus supplement for an at‑the‑market program. This structure provides flexibility to raise capital for TIGeR‑PaC and RenovoCath commercialization.
Market Pulse Summary
This announcement highlights continued commercial traction for RenovoCath, with active centers rising from 5 to 9 and about $900,000 in sales through September 2025. Filings show growing, but still modest, revenue relative to a $8.2 million nine‑month net loss and a $10.0 million cash balance. An S-3 shelf for up to $50,000,000 and an ATM facility provide capital flexibility. Key metrics to watch include center count, revenue growth, TIGeR-PaC progress, and any new financings.
Key Terms
Trans-Arterial Micro-Perfusion medical
Phase III medical
intra-arterial medical
drug-device combination medical
AI-generated analysis. Not financial advice.
MOUNTAIN VIEW, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies, today announced continued commercial momentum with a growing number of U.S. cancer centers now integrating the Company’s RenovoCath patented FDA-cleared drug-delivery device into oncology treatment programs. The Company’s TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform, enabled by the RenovoCath device, is designed to deliver chemotherapy near the tumor site, potentially enhancing therapeutic effectiveness and minimizing the systemic side effects commonly associated with traditional intravenous chemotherapy administration.
The number of active commercial cancer centers which are eligible to order and use RenovoCath has increased from five in September 2025 to nine currently and growing with the addition of City of Hope Cancer Center in Duarte, California and Moffitt Cancer Center in Tampa, Florida. This positive development is strong evidence that RenovoRx’s commercialization efforts for RenovoCath as a standalone device are taking hold in the market.
City of Hope Cancer Center’s Chief of Interventional Radiology, Dr. Jonathan Kessler, was recently featured in an interview on Spectrum News 1 SoCal, highlighting how RenovoRx’s patented TAMP therapy platform, enabled by RenovoCath, has the potential to reshape oncology management for patients diagnosed with difficult-to-treat tumors, like locally advanced pancreatic cancer. View the full interview at: https://ir.renovorx.com/news-events/clinical-news/detail/21002/new-device-delivers-targeted-chemo-for-pancreatic-cancer.
Moffitt Cancer Center also recently highlighted one pancreatic cancer patient's journey of receiving treatment with the TAMP therapy platform. View the full newsletter at: https://ir.renovorx.com/news-events/clinical-news/detail/20999/moffitt-using-new-approach-to-treat-pancreatic-cancer.
“The growing adoption of RenovoCath by esteemed institutions like City of Hope Cancer Center and Moffitt Cancer Center, amongst others, is the driver of our commercial efforts and underscores the clinical need for more targeted oncology tools,” said Shaun Bagai, CEO of RenovoRx. “We are encouraged by both the procedural feedback and the strong commercial interest we are seeing.”
Based on physician demand, in late 2024, RenovoRx made the decision to launch a small effort to organically commercialize RenovoCath as a standalone device within its FDA cleared uses. In 2025, RenovoRx generated approximately
Important lessons were learned in 2025 about customer approval processes, sales cycles, customer training, and insurance reimbursement. Encouraged by early results, RenovoRx strengthened its go-to-market strategy by establishing a small, but dedicated commercial team, including a new Senior Director of Sales and Market Development and a Director of Marketing, along with regional sales personnel, which was fully onboarded by the end of 2025. Since then, RenovoRx has seen accelerating adoption. By applying the lessons learned in 2025, RenovoRx is aiming for revenue growth in 2026, driven by increasing physician demand, effective procedural training initiatives, and heightened recognition of the differentiated value of RenovoCath’s localized, targeted drug-delivery approach.
Importantly, the number of RenovoCath active customers does not include cancer centers that are currently participating in RenovoRx’s ongoing Phase III TIGeR-PaC trial studying the Company’s drug-device combination oncology product candidate, intra-arterial gemcitabine delivery via RenovoCath (known as IAG) for the treatment of locally advanced pancreatic cancer. Such centers could transition to commercial RenovoCath customers after full enrollment in the trial in the first half of this year.
For a full list of Cancer Centers and physicians offering treatment delivered by RenovoCath, visit: https://renovocath.com/.
About RenovoCath
Based on its FDA clearance, RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to select sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use (“IFU”), please see: IFU-10004-Rev.-G-Universal-IFU.pdf.
About the TIGeR-PaC Clinical Trial
TIGeR-PaC is an ongoing Phase III randomized multi-center trial evaluating the proprietary TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of locally advanced pancreatic cancer (LAPC). RenovoRx’s first investigational drug-device combination product candidate, using the TAMP therapy platform enabled with the Company’s FDA-cleared RenovoCath® device, is designed for the intra-arterial administration of chemotherapy, gemcitabine (IAG).
About RenovoRx, Inc.
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.
RenovoRx is in the initial stages of actively commercializing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. In December 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices, and for the first nine months of 2025, approximately
RenovoRx is also evaluating its novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath, the Company’s patented, FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.
The IAG combination product candidate, which is enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA.
For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of the Company’s management made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies, (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases, and (iii) our efforts to commercialize our RenovoCath and our TAMP technology and the potential for revenue growth from such efforts. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control, and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections, and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives, and expected operating results (including related to our revenues), which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “estimates,” “intends,” and “potential,” or the negative of these terms or other comparable terminology regarding RenovoRx’s expectations strategy, plans, or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our exploration of commercial opportunities for our TAMP technology may not lead to viable, revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding-; (iii) the timing of the initiation, progress, and potential results (including the results of interim analyses) of our preclinical studies, clinical trials, and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate-;(v) that the applicable regulatory authorities may disagree with our interpretation of the data-, research, and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates, and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xx) the pricing, coverage, and reimbursement of our product candidates, if approved; and (xxi) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission.
Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.
Contact:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
T: 212-896-1254
RenovoRX@KCSA.com
FAQ
How many cancer centers are actively using RenovoCath as of January 20, 2026?
Which major centers recently adopted RenovoCath reported by RenovoRx (RNXT)?
What revenue did RenovoRx (RNXT) generate from RenovoCath sales in 2025 through September?
Will Phase III TIGeR-PaC trial centers be counted as commercial RenovoCath customers?
What steps did RenovoRx take to support RenovoCath commercialization in 2025?
How does RenovoCath deliver therapy and what platform does it enable for RNXT?
